Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases.
OBJECTIVE
The primary goal of this phase I/II study was to evaluate the feasibility, safety and efficacy of celecoxib administered concomitant to radiotherapy to treat unresectable BM.


METHODS
Patients with measurable BM by CT or MRI, unresectability criteria by a neurosurgeon and RPA-RTOG class II were eligible. Celecoxib was administered at 400 mg/day during the entire course of radiotherapy. All patients were irradiated with 60Co beams to whole-brain dose of 32 Gy (20 fractions of 1.6 Gy each two times a day with a 6 h interval between treatments) followed by a 22.4 Gy boost (same fractionation schedule) over evident lesions.


RESULTS
Twenty-seven patients were treated. The concurrent regimen was well tolerated with 15 cases of mild dyspepsia. Alopecia (NCI grades 1-2) was the most important side effect. Three patients presented rash/desquamation of moderate intensity. Radiological responses occurred in 18 of 25 valuable patients (72), with five complete responses (CR). Symptomatic responses were reported in 25 of 27 patients (92.6), with 20 CR. The overall response rate (considering complete plus partial responses) was 66.7. Percentile 50 for time-to-progression, time-to-neurological-progression and functional-independence-time were 3, 6.25 and 6.7 months, respectively. Median survival time was 8.7 months.


CONCLUSIONS
Our initial results suggest that radiotherapy plus celecoxib is safe and a possible active treatment for patients with BM. Further investigation in a randomized trial is warranted to validate its clinical utility.
Cerchietti
Leandro C A
LC
Translational Research Unit, Universidad de Buenos Aires, Argentina. lcerchie@aecom.yu.edu
Bonomi
Marcelo R
MR
Navigante
Alfredo H
AH
Castro
Monica A
MA
Cabalar
Maria E
ME
Roth
Berta M C
BM
D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D000068579:Celecoxib; D003131:Combined Modality Therapy; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D008875:Middle Aged; D011720:Pyrazoles / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D013449:Sulfonamides / Q000627:therapeutic use*; D016896:Treatment Outcome
D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D011838:Radiation-Sensitizing Agents; D013449:Sulfonamides; D000068579:Celecoxib
J Clin Oncol. 2003 Jul 15;21(14):2760-76
12860956
CNS Drugs. 2002;16(5):325-38
11994022
Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):571-4
9336134
Int J Radiat Oncol Biol Phys. 1994 May 15;29(2):243-7
8195014
Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):297-302
10661335
J Neurooncol. 1987;5(2):125-8
3668609
Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):886-94
12377342
Neurology. 1985 Feb;35(2):219-26
3969210
Am J Clin Oncol. 2001 Oct;24(5):438-42
11586092
Cardiovasc Res. 2002 Nov;56(2):214-24
12393092
Acta Oncol. 1994;33(2):139-57
8204269
Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):325-8
10974444
Gynecol Oncol. 2000 Mar;76(3):320-5
10684704
Nat Med. 1999 Dec;5(12):1418-23
10581086
Ann Neurol. 1977 Feb;1(2):201-3
889307
Clin Cancer Res. 2001 Oct;7(10):3178-85
11595712
Neurology. 1994 Apr;44(4):675-80
8164824
Clin Cancer Res. 2003 Mar;9(3):1070-6
12631609
Strahlenther Onkol. 2003 Jan;179(1):16-20
12540980
J Pharmacol Exp Ther. 2000 May;293(2):453-9
10773015
Cancer Res. 2000 Mar 1;60(5):1326-31
10728694
Am J Clin Oncol. 1982 Dec;5(6):649-55
7165009
Clin Cancer Res. 2000 Feb;6(2):701-8
10690556
Cancer Res. 1988 Jun 1;48(11):3008-13
3365690
Am J Clin Oncol. 2001 Oct;24(5):453-7
11586095
Brain Res Mol Brain Res. 2002 Aug 15;104(2):159-69
12225870
Oncogene. 1999 Dec 20;18(55):7908-16
10630643
Cancer Res. 1990 Aug 1;50(15):4473-7
2369725
Cancer Res. 2001 Jan 1;61(1):303-8
11196178
Eur J Cancer. 1995 Sep;31A(10):1580-5
7488405
Neuro Oncol. 2002 Jan;4(1):22-5
11772429
J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jan 5;783(1):207-12
12450540
Clin Cancer Res. 2001 Oct;7(10):2998-3005
11595687
Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51
9128946
J Clin Oncol. 1988 Oct;6(10):1621-4
3171627
Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):427-34
10487566
Cancer Res. 1998 Nov 15;58(22):4997-5001
9823297
Clin Cancer Res. 2000 Nov;6(11):4343-50
11106252
Cancer. 2000 Dec 15;89(12):2637-45
11135226
Clin Cancer Res. 2003 Jun;9(6):1957-71
12796357
J Natl Cancer Inst. 1999 Sep 1;91(17):1501-4
10469752
J Natl Cancer Inst. 1998 Mar 18;90(6):455-60
9521170
Cancer Res. 2000 Nov 1;60(21):6045-51
11085526
Int J Radiat Oncol Biol Phys. 1982 Feb;8(2):219-26
7085377
N Engl J Med. 2001 Aug 9;345(6):433-42
11496855
Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):1001-6
10863071
Cancer Res. 2000 Mar 1;60(5):1306-11
10728691
Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):155-9
9747833
Natl Cancer Inst Monogr. 1977 Dec;46:151-6
349394
Clin Exp Metastasis. 2000;18(1):21-7
11206834
Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):16-20
12504031
J Clin Oncol. 2000 Nov 1;18(21 Suppl):47S-53S
11060327
Clin Cancer Res. 2000 Jun;6(6):2513-20
10873107